Oppenheimer analyst Suraj Kalia initiates coverage on $Abbott Laboratories (ABT.US)$ with a buy rating, and sets the target price at $130.
According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 8.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
The firm's industry checks indicate that Q3 underlying utilization trends remained positive, even though the usual summer seasonality led to a sequential decrease in elective procedures. Additionally, investor sentiment towards MedTech stocks is favorable as the earnings season approaches, with the expectation that investors will likely persist in favoring successful and catalyst-driven names as the year comes to a close.
Abbott is described as a 'large-cap diversified healthcare play' with a dual character. On one hand, it boasts an enticing medical technology portfolio, accounting for 45% of its $42 billion global sales, with an annual growth rate of 11%-13%. On the other hand, the non-MedTech segments are growing at a lower rate, influenced by the ongoing litigation in the pediatric nutrition sector and diminishing COVID-19 diagnostics sales. It's suggested that as these pressures in the non-MedTech sectors lessen, Abbott's financial comparisons should improve by fiscal 2026, potentially leading to an uptick in sales growth to low-double-digits and an increase in EBIT margins.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Suraj Kalia首次給予$雅培 (ABT.US)$買入評級，目標價130美元。
根據TipRanks數據顯示，該分析師近一年總勝率為53.1%，總平均回報率為8.7%。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
該公司的行業調查顯示，儘管通常的夏季季節性因素導致選修程序連續減少，但第三季度的基礎利用率趨勢仍然樂觀。此外，隨着業績期的臨近，投資者對醫療科技股票的情緒良好，預計隨着業績期的臨近，投資者可能會繼續青睞成功且具有催化劑驅動力的股票。
雅培被描述爲具有雙重特徵的 「大盤多元化醫療保健公司」。一方面，它擁有誘人的醫療技術產品組合，佔其420億美元全球銷售額的45％，年增長率爲11％-13％。另一方面，受兒科營養領域正在進行的訴訟和 COVID-19 診斷銷售減少的影響，非醫療科技細分市場正以較低的速度增長。有人認爲，隨着非醫療技術領域的壓力減輕，到2026財年，雅培的財務比較將有所改善，這可能會導致銷售增長回升至低兩位數，息稅前利潤率增加。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
